| Literature DB >> 36158025 |
Hai Qu1, Yi-Hong Zhao2, Wen-Mei Zhu1, Lu Liu1, Ming Zhu1.
Abstract
BACKGROUND: Comamonas kerstersii (C. kerstersii) infections have considered as non-pathogenic to humans, however due to new techniques such as matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF-MS), more cases have been identified. CASEEntities:
Keywords: Bacteremia; Caesarean section; Case report; Comamonas kerstersii; Matrix-assisted laser desorption ionization-time of flight mass spectrometry; Metagenomic next-generation sequencing testing
Year: 2022 PMID: 36158025 PMCID: PMC9353907 DOI: 10.12998/wjcc.v10.i21.7585
Source DB: PubMed Journal: World J Clin Cases ISSN: 2307-8960 Impact factor: 1.534
Figure 1Timeline of reported events. The most relevant symptoms, diagnostics, and treatment of the patient in chronological order. POD: Postoperative day; PE: Pulmonary embolism; CT: Computed tomography; IC: Intensive care.
Figure 2Detection of pathogens by metagenomic next-generation sequencing. All the pathogens’ reads and relative abundance that were detected in blood (A) and in the posterior fornix puncture fluid (B). The coverage and proportion of Comamonas kerstersii detected by metagenomic next-generation sequencing in blood (C) and posterior fornix puncture fluid (D). Coverage is the percentage of all reads covering the reference genome, and the average depth is the reads’ read length multiplied by the number of reads divided by the size of the reference genome. The ordinate depth in the figure shows the number of times the detected pathogen sequences are compared with the reference template. The larger the depth and coverage values, the more likely the pathogen in the sample is real, and the higher the content.
Antimicrobial susceptibility of Comamonas kerstersii isolates
|
|
|
|
| Cefotaxime | 0.25 | S |
| Meropenem | 0.25 | S |
| Piperacillin-tazobartan | 0.25 | S |
| Ceftazidime | 1 | S |
| Ciprofloxacin | 4 | R |
| Gentamycin | 8 | I |
| Aztreonam | 16 | I |
| SMZ-TMP | > 32 | R |
| Cefepime | 0.5 | S |
Determined by disc diffusion. SMZ-TMP: Sulfamethoxazole-trimethoprim; MIC: Minimum inhibitory concentration; S: Sensitive; I: Intermediate; R: Resistant.